Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study

The antibody–drug conjugate (ADC) brentuximab vedotin consists of the CD30‐directed antibody attached to the microtubule‐disrupting agent monomethyl auristatin E (MMAE). In pharmacokinetic models, including data from six studies (380 patients with classical Hodgkin's, systemic anaplastic large‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Suri, Ajit, Mould, Diane R., Liu, Yi, Jang, Graham, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220930/
https://www.ncbi.nlm.nih.gov/pubmed/29377077
http://dx.doi.org/10.1002/cpt.1037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220930/
https://www.ncbi.nlm.nih.gov/pubmed/29377077
http://dx.doi.org/10.1002/cpt.1037

Ejemplares similares